Τρίτη 21 Νοεμβρίου 2017

U.S.A.latest news

H A P P Y
THANKSGIVING

Don't let Food-borne Illnesses spoil your Holiday plans. Follow these tips to make sure your Thanksgiving meal is both delicious and safe to serve!
CLEAN, SEPARATE, COOK AND CHILL
Get the Facts! STAY SAFE!
Each year millions of people get sick from food illnesses. Food illness can cause you to feel like you have the flu. Use the tips provided in this free publication to ensure you have a very
Happy Thanksgiving!

This message was sent to politikimx@yahoo.gr from:
US Government Publishing Office | pueblo@gpo.gov | GPO | 31451 United Ave | Pueblo, CO 81001

U.S. Food & Drug Administration Header
Goya de Puerto Rico is recalling 28 ounces Adobo with Cumin Seasoning and 28 ounces Adobo with Pepper Seasoning because they have the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune system. No illnesses have been reported to date.
661 cases of these products were distributed in Puerto Rico through retail stores. Goya Adobo with Cumin Seasoning is package in 28 ounces plastic jar with green cap with mark "Best by Date 10/18/22''. Goya Adobo with Pepper Seasoning is package in 28 ounces plastic jar with red cap with mark "Best by Date 10/23/22".MedWatch - The FDA Safety Information and Adverse Event Reporting Program

Limbrel Capsules by Primus Pharmaceuticals: FDA Advisory - Linked to Potentially Life-Threatening Health Problems

[Posted 11/21/2017]
AUDIENCE: Consumer, Health Professional
ISSUE: The FDA is investigating serious adverse events involving Limbrel, a product in capsule form currently being marketed as a medical food to manage the metabolic processes associated with osteoarthritis. While a range of adverse events have been reported, two serious and potentially life-threatening medical conditions are among them: drug-induced liver injury and hypersensitivity pneumonitis. In total, the FDA has received 194 adverse event reports regarding Limbrel, of those, 57 of the cases contained sufficient information to analyze in detail whether Limbrel was associated with an adverse event; 30 of these contained sufficient information to use the Council for International Organizations of Medical Sciences (CIOMS) causality assessment method to determine the likelihood that an association between the consumption of Limbrel and the adverse events reported exists.
BACKGROUND: Limbrel is marketed by Primus Pharmaceuticals Inc., Scottsdale, AZ. Limbrel is available in capsule form in two dosages: Limbrel250 and Limbrel500. The labeling states that the products contain two types of flavonoids: baicalin (from Scutellaria baicalensis) and catechin (from Acacia catechu). Both dosages also contain zinc. Claims made on the product label and in labeling indicate that Limbrel is intended to manage the metabolic processes associated with osteoarthritis.
On November 8, 2017, the FDA contacted Primus Pharmaceuticals regarding the adverse events and requested information about the formula for Limbrel. The formula is being reviewed by the FDA. In the interim, the agency is alerting consumers and health care providers about the potential impact to health and advising consumers not to use Limbrel.
The FDA is continuing to investigate Primus Pharmaceuticals and the manufacturing process for Limbrel, and will share updates as they become available.
RECOMMENDATION:
  • For Consumers: If you are taking Limbrel, immediately stop taking it and contact your health care provider.  If you have experienced any of the above-mentioned symptoms or other health problems while taking Limbrel, work with your health care provider to report your symptoms to the FDA through MedWatch.
  • For Health Professionals: Health care providers who are aware that their patients are taking Limbrel should advise them to immediately stop taking the product. If your patients have experienced any of the above-mentioned symptoms or other health problems while taking Limbrel, the FDA encourages you to work with them to provide clinical information through MedWatch.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
  • Complete and submit the report Online: www.fda.gov/MedWatch/report
  • Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Read the MedWatch Safety Alert, including a link to the FDA Drug Safety Communication, at:https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm586111.htm
For Teachers

Let Us Know in One Simple Step

Dear teacher and educator,
We periodically review our email lists to make sure we're not sending unwanted emails, and we noticed you haven't opened an email from us in a while. Please on the below link by December 30  if you'd like to continue to receive emails from us, otherwise we'll remove you from our list. We hope you stay with us!
Thank you,
The USAGov Team

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου